Uncategorized

Prostate cancer is the most common malignant tumor of the male urinary reproductive system. Compared to developed countries, China has a higher proportion of late-stage prostate cancer patients at diagnosis, resulting in poorer prognosis. In recent years, there have been rapid advancements in prostate cancer research. Therefore, developing diagnosis and treatment guidelines tailored to China based on the latest evidence-based medicine is crucial for the early diagnosis, treatment, and prognosis of Chinese prostate cancer patients. As the 2024 CSCO Guidelines Conference approaches, "Oncology Frontier" invited Prof. Dingwei Ye, Chair of the CSCO Prostate Cancer Committee and a professor at Fudan University Cancer Hospital, to discuss the guidelines.

Editor's Note: The 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), hosted by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), concluded successfully in…

On March 30, 2024, the First Academic Forum of the Ocular Lymphoma Collaboration Group was successfully held in Beijing. It was hosted by Beijing Tongren Hospital affiliated with Capital Medical University, China Human Health Technology Promotion Association, Beijing Public Health Science Popularization Promotion Association, and Beijing Chen Jumei Charity Foundation. The event was organized by the Cell Immunotherapy Committee of the China Human Health Technology Promotion Association. Renowned experts and scholars from both domestic and international communities actively exchanged ideas and engaged in discussions about the latest advancements and hot topics in the diagnosis and treatment of ocular lymphoma. Professor Lei Fan from Jiangsu Provincial People's Hospital was specially invited by "Oncology Frontier - Hematology Frontier" to share updates in the research on improving prognosis, novel biomarkers, and prevention of recurrence in the internal medicine treatment of ocular lymphoma.

In September 2023, a pivotal study led by professor Erlie Jiang from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science was published in Hematology, focusing on acute myeloid leukemia (AML) patients in their first remission and comparing outcomes between autologous, matched sibling, and alternative donor stem cell transplants. This research innovatively applied propensity score matching to dissect and evaluate the nuances of transplant efficacy and safety across different donor types. By conducting a thorough and detailed comparison, Jiang and her collaborative team have markedly advanced the understanding of optimal transplant strategies for AML treatment. Their work illuminates the path toward enhancing patient survival rates and quality of life through informed donor selection, underscoring the study’s significance in the realm of personalized AML care. Through this study, Erlie Jiang and her colleagues have made a substantial contribution to refining clinical decision-making in the selection of stem cell transplant donors for AML patients.